Virtual Library
Start Your Search
Leon Raskin
Author of
-
+
P2.12 - Small Cell Lung Cancer/NET (ID 180)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.12-17 - Treatment Patterns in Small Cell Lung Cancer (SCLC): An Observational Study of 2016–2018 EHR Data (ID 666)
10:15 - 18:15 | Author(s): Leon Raskin
- Abstract
Background
SCLC is an aggressive neuroendocrine malignancy with a poor prognosis. Treatment for SCLC has remained largely unchanged for more than two decades, and treatment options for patients remain limited. Recently, immune checkpoint inhibitors have shown efficacy either in combination with chemotherapy in first line or as monotherapy in second or later lines. To better characterize the SCLC treatment landscape, we investigated treatment patterns in a large electronic health record (EHR) dataset.
Method
Patients ≥18 years of age diagnosed with SCLC from 2016 through 2018 at a US Oncology Network or Onmark community oncology practice were included. Patients enrolled in clinical trials were excluded. Baseline characteristics were compared between treated and untreated patients, and treatment regimens were described by year and by line of therapy.
Result
A total of 4,589 patients were diagnosed with SCLC during the study period, of whom 85% were treated. Demographics and disease characteristics were similar between treated and untreated groups. Patients were predominately female, former smokers, and residents of the southern United States. Approximately 33% of the treated patients had at least 2 lines of therapy, and 9% had at least 3 lines. The most commonly used treatment regimen in first line across years was platinum + etoposide ± other; in second line, topotecan and nivolumab were most common; in third or later lines, paclitaxel, topotecan, and nivolumab were most common. See Table for details.
Conclusion
In this database of community oncology practices covering 2016-2018, platinum-based chemotherapy regimens were the most commonly used treatments for patients with SCLC across lines of therapy and years. Other commonly used chemotherapy agents included topotecan, paclitaxel, and irinotecan. Immune checkpoint inhibitors were used predominantly in second and third lines, and utilization increased from 2016 to 2018.